Showing 3741-3750 of 7113 results for "".
- Regenerative Medicine in Action: Scarless Wound Recovery May Be Possible with New Autologous Blood Techniquehttps://practicaldermatology.com/news/regenerative-medicine-in-action-scarless-wound-recovery-may-be-possible-with-new-autologous-blood-technique/2461982/A new technology that utilizes autologous blood to produce three-dimensional microvascular implants may help make scarless wound recovery a reality. Led by Professor Joo H. Kang from the Department of Biomedical Engineering at UNIST, the team developed a microfluidic system capable
- TikTok Trend Watch: Is Beer Tanning Really a Thing?https://practicaldermatology.com/news/tik-tok-trend-watch-is-beer-tanning-really-a-thing/2461976/TikTok is where many trends and DIY challenges get started, and skincare is one of the more popular categories for this content, for better or sometimes for worse. Take beer tanning, for example. Tik Tokkers are claiming that pouring beer on skin will activate melanin for a better
- Christopher G. Bunick, MD, PhD, Receives the American Acne and Rosacea Society's 2023 Research Scholar Awardhttps://practicaldermatology.com/news/christopher-g-bunick-md-phd-receives-american-acne-and-rosacea-society-announces-2023-research-scholar-award/2461962/Christopher G. Bunick, MD, PhD, has received The American Acne and Rosacea Society’s (AARS) 2023 Research Scholar Award. Dr. Bunick is an Associate Professor of Dermatology at Yale University School of Medicine and a member of the Practical Dermatology magazine editorial board.</
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- New Report Highlights Challenges in Evaluating Biosimilarshttps://practicaldermatology.com/news/new-report-highlights-challenges-in-evaluating-biosimilars/2461933/New research provides an overview of gaps and challenges in the value assessment of biosimilars and identifies potential approaches to address them. The report, “
- Regenerative Medicine in Action: Turn Bio's ERA Technology Reprograms Skin Cellshttps://practicaldermatology.com/news/regenerative-medicine-in-action-turn-bios-era-technology-reprograms-skin-cells/2461930/Reprogramming with Turn Bio's ERA technology can rejuvenate cells within the extracellular matrix (ECM), resulting in changes related to improved skin quality and structure, according to a presentation at the AAD 2023 Innovation Academy in Tampa, Fla. ERA reprogramming tec
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic
- Bristol Myers Squibb’s New Sotyktu Campaign Reveals the Plain Truth About Living With Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibbs-new-clear-understanding-campaign-reveals-the-plain-truth-about-living-with-moderate-to-severe-plaque-psoriasis/2461914/Bristol Myers Squibb is rolling
- Evolus Rolls Out New Branding for Jeuveauhttps://practicaldermatology.com/news/evolus-rolls-out-new-branding-for-jeuveau/2461913/Evolus, Inc. is unveiling its new branding for Jeuveau (prabotulinumtoxinA-xvfs). The new Jeuveau imagery reflects today’s consumers, many of whom are millennials and younger. The “Jeuveau, You See Me” marketing campaign uses inclusive messaging to encourage